2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-12141
    Vestipitant mesylate 334476-64-1 98%
    Vestipitant (GW597599) mesylate is a selective, orally active, and blood-brain barrier penetrant NK1 receptor antagonist. Vestipitant mesylate exhibits high affinity for the human NK1 receptor (pKi: 9.65). Vestipitant mesylate can be used in the research of diseases such as depression, anxiety disorders, and nausea and vomiting.
    Vestipitant mesylate
  • HY-12144
    CP-99994 136982-36-0 98%
    CP-99994 is a Tachykinin neurokinin 1 (NK-1) receptor antagonist with a Ki of 0.25 nM. CP-99994 prevents colorectal sensitization in the context of visceral hypersensitivity. CP-99994 reduces colorectal hypersensitivity induced by acetic acid injections in a model of bladder-colon cross-sensitization. CP-99994 hydrochloride attenuates the neuroglial interactions and MAPK-p38 phosphorylation associated with visceral hypersensitivity.
    CP-99994
  • HY-12145
    CP-99994 hydrochloride 145148-39-6 98%
    CP-99994 hydrochloride is a Tachykinin neurokinin 1 (NK-1) receptor antagonist with a Ki of 0.25 nM. CP-99994 hydrochloride prevents colorectal sensitization in the context of visceral hypersensitivity. CP-99994 hydrochloride reduces colorectal hypersensitivity induced by acetic acid injections in a model of bladder-colon cross-sensitization. CP-99994 hydrochloride attenuates the neuroglial interactions and MAPK-p38 phosphorylation associated with visceral hypersensitivity.
    CP-99994 hydrochloride
  • HY-12153
    JNJ-1930942 929562-28-7 98%
    JNJ-1930942 is a selective and blood-brain barrier (BBB) penetrant α(7) nAChR positive allosteric modulator.JNJ-1930942 enhances the Choline (HY-B0282)-evoked rise in intracellular Ca2+ levels and neurotransmission at hippocampal dentate gyrus synapses. JNJ-1930942 reverses the naturally occurring sensory gating deficit in DBA/2 mice.
    JNJ-1930942
  • HY-12155
    JNJ-26990990 877316-38-6 98%
    JNJ-26990990 is a broad-spectrum antiepileptic agent with oral activity. JNJ-26990990 can inhibit voltage-gated Na+ channels and N-type Ca2+ channels, but has a very weak inhibitory effect on human carbonic anhydrase-II (IC50 = 110 μM).
    JNJ-26990990
  • HY-12237
    SKF 38393 hydrobromide 20012-10-6 98%
    SKF 38393 ((±)-SKF-38393) hydrobromide is a selective agonist of the dopamine D1 receptor (D1DR) with an IC50 of 110 nM.
    SKF 38393 hydrobromide
  • HY-12244
    BB-22 1400742-42-8 98%
    BB-22 is a cannabinoid wih dopamine (DA) stimulant properties. BB-22 shows affinity to CB1 receptors with a Ki value of 0.11 nM and an EC50 value of 2.9 nM.
    BB-22
  • HY-12327
    Trk-IN-1 1402438-37-2 98%
    Trk-IN-1 (example 9), a potent tropomyosin-related kinase (Trk) inhibitor, shows potency against TrkA (3.7 nM) and TrkB (94 nM), respectively.
    Trk-IN-1
  • HY-12328
    Trk-IN-2 1614229-04-7 98%
    Trk-IN-2 is an orally active pan-Trk kinase inhibitor with an TrkA IC50 of 9 nM. Trk-IN-2 exhibits pharmacodynamic effects in rat models of inflammatory pain and neuropathic pain.Trk-IN-2 can be used for the research of inflammatory pain, neuropathic pain.
    Trk-IN-2
  • HY-12371
    VU0431316 1620203-63-5 98%
    VU0431316 is a potent and selective non-competitive antagonist of mGlu5 with an IC50 value of 24 nM.
    VU0431316
  • HY-12389
    8-Hydroxyamoxapine 61443-78-5 98%
    8-Hydroxyamoxapine is an orally active antidepressant, which inhibits the reuptake of norepinephrine and serotonin at synapses.
    8-Hydroxyamoxapine
  • HY-12520
    SKF 38393 67287-49-4 98%
    SKF 38393 is a selective dopamine D1 receptor agonist. SKF 38393 activates the cAMP signaling pathway and promotes dopamine release in the developing rat striatum. SKF 38393 inhibits MCF-7 breast cancer cell proliferation (IC50=0.1 μM). SKF 38393 is promising for research of neurodevelopmental disorders, dopamine-related diseases (e.g., Parkinson’s, dopamine deficiency), and cancers.
    SKF 38393
  • HY-12535
    Trichodesmine 548-90-3 98%
    Trichodesmine is a dehydropyrrolizidine alkaloid. Trichodesmine can produces hepatotoxicty, pneumo- and neurotoxicity in vivo.
    Trichodesmine
  • HY-12560
    PNU-282987 free base 711085-63-1 98%
    PNU-282987 (free base) is a potent α7 nicotinic acetylcholine receptor (nAChR) agonist with an EC50 of 154 nM. PNU-282987 (free base) is also a functional antagonist of the 5-HT3 receptor with an IC50 of 4541 nM. PNU-282987 (free base) can be used for the research of central and peripheral nervous systems.
    PNU-282987 free base
  • HY-12596
    JNJ-26489112 871824-55-4 99.31%
    JNJ-26489112, a CNS-active agent, exhibits broad-spectrum anticonvulsant activity in rodents against audiogenic, electrically-induced, and chemically-induced seizures. JNJ-26489112 inhibits voltage-gated Na+ channels and N-type Ca2+ channels, and is effective as a K+ channel opener. JNJ-26489112 has very weak inhibition of CA-II (IC50=35 μM) and CA-I (18 μM).
    JNJ-26489112
  • HY-12701
    U-99194 82668-33-5 98%
    U-99194 (PNU-99194) is a selective, potent dopamine D3 receptor antagonist. U-99194 inhibits the activation of D3 receptor mediated by endogenously released dopamine or exogenous D3 agonists. U-99194 abrogates the IPSC-suppressive effect of the D3 agonist PD 128907 in rat hippocampal slices. U-99194 significantly suppresses Nicotine (HY-127019)-induced tremor in mice. U-99194 can be used for the study of dopamine D3 receptor-mediated motor disorders, particularly kinetic tremors.
    U-99194
  • HY-12705
    Bromocriptine 25614-03-3 98%
    Bromocriptine is a potent dopamine D2/D3 receptor agonist, which binds D2 dopamine receptor with pKi of 8.05±0.2.
    Bromocriptine
  • HY-12712
    L-657743 111466-41-2 98%
    L-657743 is a highly potent, highly selective, and orally active α2-adrenoceptor antagonist. L-657743 can be used in the research of neurological diseases such as depression.
    L-657743
  • HY-12716
    BRL-44408 118343-19-4 98%
    BRL-44408 is a selective, blood-brain barrier-permeable α2A-adrenergic receptor antagonist with a Ki value of 8.56 nM against human targets. BRL-44408 exhibits activities such as antidepressant, analgesic effects and attenuation of sepsis-induced acute lung injury by regulating the release of neurotransmitters such as norepinephrine and dopamine, or inhibiting signaling pathways including ERK1/2, p38MAPK and p65. BRL-44408 can be used in studies related to acute respiratory distress syndrome, depression and visceral pain.
    BRL-44408
  • HY-12720
    Apraclonidine 66711-21-5 98%
    Apraclonidine (ALO 2145 (free base)), a selective α2 and weak α1 receptor agonist activity, effectively low intraocular pressure (IOP) in human eyes. Apraclonidine hydrochloride is a topical ophthalmic solution.
    Apraclonidine
Cat. No. Product Name / Synonyms Application Reactivity